A brief insight into systemic lupus erythematosus pathogenesis
Abstract
Keywords
Full Text:
PDFReferences
Doria A, Zen M, Bettio S, et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev 2012; 12:22-30.
Singh RP, Waldron RT, Hahn BH. Genes, tolerance and systemic autoimmunity. Autoimmun Rev 2012; 11:664-669.
Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58(22):15-25.
Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58(1):26-35.
Abdwani R, Rizvi SG, El-Nour I. Childhood systemic lupus erythematosus in Sultanate of Oman: demographics and clinical analysis. Lupus 2008; 17:683-686.
Barron KS, Silverman ED, Gonzales J, Reveille JD. Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1993; 36:348-354.
Font J, Cervera R, Espinosa G, et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998; 57:456-459.
Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008; 152:550-556.
Hoffman IE, Lauwerys BR, De Keyser F, et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 2009; 68:412-415.
Mahmoud SS, Bazaraa HM, Lotfy HM, Abd-El-Aziz DM. Renal involvement in childhood-onset systemic lupus erythematosus in Egypt. Rheumatol Int 2012; 32:47-51.
Jacobsen S, Petersen J, Ullman S, et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clin Rheumatol 1998; 17:468-477.
Seligman VA, Lum RF, Olson JL, et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002; 112:726-729.
Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus - an update. Curr Op Immunol 2012; 24:651-657.
Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nature Rev Nephrol 2015; 11:329-341.
Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358(9):929-939.
Crow MK. Collaboration, genetic associations, and lupus erythematosus. N Engl J Med 2008; 358(9):956-961.
Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis 2014; 73:1601-1606.
Shah D, Mahajan N, Sah S, et al. Oxidative stress and its biomarkers in systemic lupus erythematosus. J Biomed Sci 2014; 21(1):23.
Wu T, Qin X, Kurepa Z, et al. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest 2007; 117:2186-2196.
Sang A, Zheng Y Y, Morel L. Contributions of B cells to lupus pathogenesis. Mol Immunol 2014; 62:329–338.
Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med 1993; 177:999-1008.
Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med 1993;177:1009-1020.
Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377.
Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008; 28:18-28.
Chan TD, Brink R. Affinity-based selection and the germinal center response. Immunol Rev 2012; 247:11-23.
Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Ann Rev Immunol 2007; 25:419-441.
Rifkin IR, Leadbetter EA, Beaudette BC, et al. Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. J Immunol 2000; 165:1626-1633.
Crispín JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:317-325.
Liossis SN, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated proteintyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 1998; 101:1448-1457.
Enyedy EJ, Nambiar MP, Liossis SN, et al. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:1114-1121.
Krishnan S, Juang YT, Chowdhury B, et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 2008; 181:8145-8152.
Deng GM, Liu L, Bahjat FR, et al. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010; 62:2086-2092.
Strasser A, Jost P, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30:180–192.
Blank U, Essig M, Scandiuzzi L, et al. Mast cells and inflammatory kidney disease. Immunol Rev 2007; 217:79-95.
Eddy AA. Mast cells find their way to the kidney. Kidney Int 2001; 60:375-377.
Pelletier C, Guerin-Marchand C, Iannascoli B, et al. Specific signaling pathways in the regulation of TNF-alpha mRNA synthesis and TNF-alpha secretion in RBL-2H3 mast cells stimulated through the high affinity IgE receptor. Inflamm Res 1998; 47:493-500.
Lin L, Gerth AJ, Peng SL. Susceptibility of mast cell-deficient W/Wv mice to pristane-induced experimental lupus nephritis. Immunol Lett 2004; 91:93-97.
Charles N, Hardwick D, Daugas E, et al. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 2010; 16:701-707.
Sekine H, Ruiz P, Gilkeson GS, Tomlinson S. The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol 2011; 49(1–2):317-323.
Wang G, Pierangeli SS, Papalardo E, et al. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010; 62(7):2064-2072.
Ben Mansour R, Lassoued S, Elgaied A, et al. Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 2010; 39(3):247-253.
Perl A. Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity 2010; 43(1):1-6.
Hassan SZ, Gheita TA, Kenawy SA, et al. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis 2011; 14(4):325-331.
Gheita TA, Kenawy SA. Measurement of malondialdehyde, glutathione, and glutathione peroxidase in SLE patients. Methods Mol Biol 2014; 1134:193-199.
Sekine H, Kinser TT, Qiao F, et al. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 2011; 63:1076-1085.
Kerboua KE, Boumediene A, Haiba F, Batouche D. The alternative complement pathway activity may depend on plasma malondialdehyde level in systemic lupus erythematosus patients: Preliminary results. Egypt Rheumatol 2016; DOI: 10.1016/j.ejr.2016.02.003.
Oates JC. The biology of reactive intermediates in systemic lupus erythematosus. Autoimmunity 2010; 43:56–63.
Perl A. Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren’s syndrome. Curr Opin Rheumatol 2009; 21(5):443-447.
DOI: http://dx.doi.org/10.22551/2016.10.0301.10066
Copyright (c) 2016 Archive of Clinical Cases
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ISSN: 2360-6975